Home » NAUTILUS BIOTECH AND ANGEL BIOTHECHNOLOGY SIGN AGREEMENT TO MANUFACTURE BELEROFON (IMPROVED ALPHA INTERFERON) FOR PHASE I CLINICAL TRIALS
NAUTILUS BIOTECH AND ANGEL BIOTHECHNOLOGY SIGN AGREEMENT TO MANUFACTURE BELEROFON (IMPROVED ALPHA INTERFERON) FOR PHASE I CLINICAL TRIALS
Nautilus Biotech a protein pharmaceuticals private company and Angel Biotechnology a UK private company providing world-class contract manufacturing services in microbial fermentation and mammalian cell culture, announced today that they have signed an agreement for the manufacture of Nautilus' improved alpha interferon (Belerofon) for Phase I clinical development.
Wall Street Reporter (http://www.wallstreetreporter.com/companies/NautilusBiotech1.html)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23May
-
30May
-
13Jun
-
20Jun
-
21Oct